Drugs / OSI-930
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00603356 | Nov 2007 → Apr 2010 | cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT00513851 | Apr 2006 → Jul 2009 | — | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OSI-930 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00513851 ↗ |
| Action | Inhibit | “Stem cell growth factor receptor inhibitor” CHEMBL1614710 ↗ |
| Modality | Small molecule | — CHEMBL1614710 ↗ |
| Route | Oral | “Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity” NCT00513851 ↗ |
| Target | KIT | “Stem cell growth factor receptor inhibitor” CHEMBL1614710 ↗ |